Drug Development
Drug developer sets $15 million financing, renin inhibitor collaboration
Published in Medical Letter on the CDC and FDA, August 21st, 2005
As part of the formal completion of the transaction with GSK, Vitae secured $15 million in equity financing from investors, which the company intends to use principally to accelerate its multiple programs into the clinic.
GSK and Vitae formed a strategic alliance in June 2005 to develop and commercialize renin inhibitor drug compounds for the treatment of hypertension and related cardiovascular disorders. As part of this...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Anthrax Vaccine
Adverse events reported by participants in CDC anthrax program reviewed - Fetal Loss Risk Factors
Elevated factor VII is risk factor for recurrent fetal loss - Hepatocellular Cancer
SEN virus infection not major cause of hepatocellular carcinoma - Malaria Diagnosis
Malaria screening and treatment of refugees from Cambodia described - Poliovirus Genomics and Genetics
Genomic analysis of vaccine-derived poliovirus strains reported - Acinetobacter Baumannii Outbreak
Carbapenem-resistant Acinetobacter baumannii cause of hospital outbreak - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
